Region: Australia

Surging litigation numbers and public distrust plague life sciences landscape

From trade secrets to overregulation, there are many core threats to the global life sciences arena. But expert advice outlines strategic ways to neutralise them

05 September 2023

‘IP is a long game’ – an interview with Breville’s head of corporate development

Jarred Twigg, who stepped down as head of IP last July, talks to IAM about the sometimes ‘uncomfortable truth’ of intellectual property and ‘winning the moments’

05 September 2023

Australia: patent-term extension developments and challenges

Featured in The Guide to Life Sciences: Key issues for senior life sciences executives 2023

PTEs in the pharmaceutical space are a key way for innovators to recoup R&D costs – however, they are often challenged by generics manufacturers. An uptick of such cases in Australia could prompt a reassessment of how courts handle such issues, which would have a significant knock-on effect on the country’s life sciences landscape.

25 August 2023

Australia: Three Superior Court Decisions Look Set to Have Serious Patent Implications

Featured in Asia-Pacific Patent Litigation Review 2024

The last year may well prove to be a pivotal one for Australian IP litigation, with cases that touch upon subjects as diverse as eligibility requirements for computer-implemented inventions, damages for higher prices paid to a pharmaceutical company during a preliminary injunction and whether AI platforms are entitled to apply for patents.

25 August 2023

Featured in Special Report 2022 Q4: Trade secret strategy playbook

16 November 2022

How ResMed uses IP to build business value

Michael Pinczuk and his colleague Keira Moore explain that deep thinking about strategy and communication have paid dividends for the leading medtech company

29 July 2022

Australia & New Zealand

Featured in Special Report 2022 Q2: The Asia IP Elite

30 May 2022